Jundishapur Journal of Microbiology

Published by: Kowsar

Production of IFN-γ and IL-4 Against Intact Catalase and Constructed Catalase Epitopes of Helicobacter pylori From T-Cells

Hajieh Ghasemian Safaei 1 , Jamshid Faghri 1 , Sharareh Moghim 1 , Bahram Nasr Esfahani 1 , Hossein Fazeli 1 , Manoochehr Makvandi 2 , Minoo Adib 3 and Niloufar Rashidi 4 , 5 , *
Authors Information
1 Department of Microbiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of Virology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
4 Department of Laboratory Sciences, Paramedical School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
5 Research Institute for Infectious Disease of Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: December 2015, 8 (12); e59921
  • Published Online: December 13, 2015
  • Article Type: Research Article
  • Received: November 12, 2014
  • Revised: September 30, 2015
  • Accepted: October 4, 2015
  • DOI: 10.5812/jjm.24697

To Cite: Ghasemian Safaei H, Faghri J, Moghim S, Nasr Esfahani B, Fazeli H, et al. Production of IFN-γ and IL-4 Against Intact Catalase and Constructed Catalase Epitopes of Helicobacter pylori From T-Cells, Jundishapur J Microbiol. 2015 ; 8(12):e59921. doi: 10.5812/jjm.24697.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Shi Y, Wu C, Zhou WY, Mao XH, Guo G, Zou QM. Identification of H-2d restricted Th epitopes in Urease B subunit of Helicobacter pylori. Vaccine. 2007; 25(14): 2583-90[DOI][PubMed]
  • 2. Zhao W, Wu W, Xu X. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice. Vaccine. 2007; 25(44): 7664-73[PubMed]
  • 3. Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj-Elliott M. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter. 2006; 11(2): 113-22[DOI][PubMed]
  • 4. Czinn SJ. Helicobacter pylori infection: detection, investigation, and management. J Pediatr. 2005; 146(3 Suppl)-6[DOI][PubMed]
  • 5. Li GQ, Chen MH, Zhu SL, Chen J, Jiao ZY, Chen W, et al. Therapeutic vaccination against Helicobacter pylori infection with attenuated recombinant Salmonella typhimurium urease B subunit and catalase in mice. Chinese j digestive dis. 2004; 5(2): 72-5[DOI]
  • 6. Chen M, Chen J, Liao W, Zhu S, Yu J, Leung WK, et al. Immunization with attenuated Salmonella typhimurium producing catalase in protection against gastric Helicobacter pylori infection in mice. Helicobacter. 2003; 8(6): 613-25[PubMed]
  • 7. Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2011; 8(3): 133-40[DOI][PubMed]
  • 8. Li HB, Zhang JY, He YF, Chen L, Li B, Liu KY, et al. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine. 2012; 31(1): 120-6[DOI][PubMed]
  • 9. Khan AM, Miotto O, Heiny AT, Salmon J, Srinivasan KN, Nascimento EJ, et al. A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol. 2006; 244(2): 141-7[DOI][PubMed]
  • 10. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine. 2001; 19(31): 4385-95[PubMed]
  • 11. Rashidi N, Moghim S, Fagheri J, SAFAEI HG. Catalase epitopes vaccine design for Helicobacter pylori: A bioinformatics approach. Afr J Biotech. 2011; 10: 8895-901
  • 12. Totally synthetic peptide-based vaccines that target dendritic cells and induce potent antibody or CTL responses. International congress series. : 311-5
  • 13. Miyashita M, Joh T, Watanabe K, Todoroki I, Seno K, Ohara H, et al. Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine. 2002; 20(17-18): 2336-42[PubMed]
  • 14. Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun. 1997; 65(11): 4668-74[PubMed]
  • 15. Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, et al. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine. 2009; 27(36): 5013-9[DOI][PubMed]
  • 16. Torres J, Perez-Perez G, Goodman KJ, Atherton JC, Gold BD, Harris PR, et al. A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res. 2000; 31(5): 431-69[PubMed]
  • 17. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, et al. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods. 2004; 34(4): 476-87[DOI][PubMed]
  • 18. Dubois A, Boren T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol. 2007; 9(5): 1108-16[DOI][PubMed]
  • 19. Chu YT, Wang YH, Wu JJ, Lei HY. Invasion and multiplication of Helicobacter pylori in gastric epithelial cells and implications for antibiotic resistance. Infect Immun. 2010; 78(10): 4157-65[DOI][PubMed]
  • 20. Safaei HG,, Rashidi N:. Comparison of Salivary Anti Helicobacter pylori IgG with Serum IgG and Bacterio-logical Tests in Detecting Helicobacter pylori Infections. J Res Med Sci. 2005; 1: 1-5
  • 21. Poddar U, Yachha SK. Helicobacter pylori in children: an Indian perspective. Indian Pediatr. 2007; 44(10): 761-70[PubMed]
  • 22. Hardin FJ, Wright RA. Helicobacter pylori: review and update. Hosp Physician. 2002; 38(5): 23-31
  • 23. Suzuki T, Iwasaki E, Tsuchimoto KH, Nishizawa T, Masaoka T, Mori M. Helicobacter pylori infection and gastric cancer. J M A. 2009; 14: 497
  • 24. Aebischer T, Walduck A, Schroeder J, Wehrens A, Chijioke O, Schreiber S, et al. A vaccine against Helicobacter pylori: towards understanding the mechanism of protection. Int J Med Microbiol. 2008; 298(1-2): 161-8[DOI][PubMed]
  • 25. Arnold IC, Hitzler I, Engler D, Oertli M, Agger EM, Muller A. The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia. J Immunol. 2011; 186(11): 6165-72[DOI][PubMed]
  • 26. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002; 16 Suppl 1: 3-15[PubMed]
  • 27. Alvandi A, Farajzadeh A, Ghaforian BM, Jelodar A, Aryan E, Gholipour A, et al. Periplasmic expression and one-step purification of urease subunit B of Helicobacter pylori. W J Microbiol Biotech. [DOI]
  • 28. Del Giudice G, Michetti P. Inflammation, immunity and vaccines for Helicobacter pylori. Helicobacter. 2004; 9 Suppl 1: 23-8[DOI][PubMed]
  • 29. Li Y, Ning YS, Wang YD, Luo J, Wang W, Dong WQ, et al. Production of mouse monoclonal antibodies against Helicobacter pylori Catalase and mapping the antigenic epitope by phage display library. Vaccine. 2008; 26(9): 1263-9[DOI][PubMed]
  • 30. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006; 19(3): 449-90[DOI][PubMed]
  • 31. Rizos K, Lattemann CT, Bumann D, Meyer TF, Aebischer T. Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains. Infect Immun. 2003; 71(11): 6320-8[PubMed]
  • 32. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine. 2011; 29(11): 2085-91[DOI][PubMed]
  • 33. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, Martin WD, et al. Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori. Hum Vaccin. 2008; 4(3): 219-23[PubMed]
  • 34. Prinz C, Hafsi N, Voland P. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends in microbiol. 2003; 11(3): 134-8[DOI]
  • 35. Akhiani AA, Stensson A, Schon K, Lycke NY. IgA antibodies impair resistance against Helicobacter pylori infection: studies on immune evasion in IL-10-deficient mice. J Immunol. 2005; 174(12): 8144-53[PubMed]
  • 36. Fernando N, Holton J, Zulu I, Vaira D, Mwaba P, Kelly P. Helicobacter pylori infection in an urban African population. J Clin Microbiol. 2001; 39(4): 1323-7[DOI][PubMed]
  • 37. Ek C, Whary MT, Ihrig M, Bravo LE, Correa P, Fox JG. Serologic evidence that ascaris and toxoplasma infections impact inflammatory responses to Helicobacter pylori in Colombians. Helicobacter. 2012; 17(2): 107-15[DOI][PubMed]
  • 38. Whary MT, Sundina N, Bravo LE, Correa P, Quinones F, Caro F, et al. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2005; 14(6): 1464-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments